Cost-effectiveness of Rotavirus vaccination in Vietnam

详细信息    查看全文

• 作者：Sun-Young Kim (1) (3)
  Sue J Goldie (1) (3)
  Joshua A Salomon (1) (2) (3)
  
• 刊名：BMC Public Health
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：9
• 期：1
• 全文大小：682KB
• 参考文献：1. Kosek M, Bern C, Guerrant RL: The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. / Bull World Health Organ 2003, 81 (3) : 197-04.
  2. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI: Global illness and deaths caused by rotavirus disease in children. / Emerg Infect Dis 2003, 9 (5) : 565-2.
  3. Santos N, Hoshino Y: Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. / Rev Med Virol 2005, 15: 29-6. CrossRef
  4. Arista S, Giammanco GM, De Grazia S, Ramirez S, Lo Biundo C, Colomba C, / et al.: Heterogeneity and temporal dynamics of evolution of G1 human rotaviruses in a settled population. / J Virol 2006, 80 (21) : 10724-3. CrossRef
  5. Trinh QD, Nguyen TA, Phan TG, Khamrin P, Yan H, Hoang PL, / et al.: Sequence analysis of the VP7 gene of human rotavirus G1 isolated in Japan, China, Thailand, and Vietnam in the context of changing distribution of rotavirus G-types. / J Med Virol 2007, 79 (7) : 1009-6. CrossRef
  6. Zahn M, Marshall GS: Clinical and epidemiological aspects of rotavirus infection. / Pediatr Ann 2006, 35 (1) : 23-.
  7. Moulton LH, Staat MA, Santosham M, Ward RL: The protective effectiveness of natural rotavirus infection in an American Indian population. / J Infect Dis 1998, 178: 1562-6. CrossRef
  8. Velazquez FR, Matson DO, Calva JJ, / et al.: Rotavirus infections in infants as protection against subsequent infections. / N Engl J Med 1996, 335: 1022-. CrossRef
  9. Cook SM, Glass RI, LeBaron CW, Ho M-S: Global seasonality of rotavirus infections. / Bull World Health Organ 1990, 68: 171-7.
  10. Centers for Disease Control and Prevention: Prevention of Rotavirus Gastroenteritis Among Infants and Children / MMWR Recomm Rep 2006, 55 (RR-12) : 1-3.
  11. WHO: Rotavirus Vaccines. / Weekly Epidemiological Record 2007, 82 (32) : 285-96.
  12. Dennehy PH: Rotavirus vaccines–an update. / Vaccine 2007, 25 (16) : 3137-1. CrossRef
  13. Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, Rheingans R, Tho le H, Glass RI, Bresee JS: Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. / J Infect Dis 2005, 192 (10) : 1720-. CrossRef
  14. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R: Projected cost-effectiveness of rotavirus vaccination for children in Asia. / J Infect Dis 2005, 192 (Suppl 1) : S133-5. CrossRef
  15. Isakbaeva ET, / et al.: Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine. / Vaccine 2007, 25: 373-80. CrossRef
  16. Jit M, Edmunds WJ: Evaluating rotavirus vaccination in England and Wales: Part II. The potential cost-effectiveness of vaccination. / Vaccine 2007, 25: 3971-979. CrossRef
  17. Lorgelly PK, / et al.: Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. / Epidemiol Infect 2007, 136 (1) : 44-5.
  18. Widdowson MA: Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States. / Pediatrics 2007, 119 (4) : 684-97. CrossRef
  19. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T: Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. / Rev Panam Salud Publica 2007, 21 (4) : 205-16.
  20. Melliez H, Levybruhl D, Boelle PY, Dervaux B, Baron S, Yazdanpanah Y: Cost and cost-effectiveness of childhood vaccination against rotavirus in France. / Vaccine 2008, 26 (5) : 706-5. CrossRef
  21. Newall AT, Beutels P, Macartney K, Wood J, MacIntyre CR: The cost-effectiveness of rotavirus vaccination in Australia. / Vaccine 2007, 25 (52) : 8851-0. CrossRef
  22. Goossens LM, Standaert B, Hartwig N, H?vels AM, Al MJ: The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. / Vaccine 2008, 26 (8) : 1118-7. CrossRef
  23. Soarex PC, Valentim J, Sartori AMC, Novaes HMD: Cost-effectiveness análisis of routine rotavirus vaccination in Brazil. / Rev Panam Salud Publica 2008, 23 (4) : 221-30.
  24. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R: Cost-effectiveness of introducing a rotavirus vaccine in developing countries: The case of Mexico. / BMC Infectious Diseases 2008, 8: 103. CrossRef
  25. Nakagomi O, Cunliffe NA: Rotavirus vaccines: entering a new stage of deployment. / Current Opinion in Infectious Diseases 2007, 20: 501-07. CrossRef
  26. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, / et al.: Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. / N Engl J Med 2006, 354 (1) : 11-2. CrossRef
  27. Linhares AC, Ruiz-Palacios GM, Guerrero ML, Salinas B, Perez-Schael I, Clemens SA, / et al.: A short report on highlights of world-wide development of RIX4414: a Latin American experience. / Vaccin 2006, 24 (18) : 3784-. CrossRef
  28. UNICEF: The State of the World's Children 2006. The United Nations Children's Fund (UNICEF), New York 2005.
  29. WHO: The World Health Report 2002: Reducing Risks, Promoting Healthy Life. World Health Organization 2002.
  30. Glass RI, Parashar UD, Bresee JS, / et al.: Rotavirus vaccines: current prospects and future challenges. / Lancet 2006, 368: 323-32. CrossRef
  31. Salinas B, Pérez-Schael I, Linhares A, Ruiz-Palacios G, Guerrero ML, Yarzabal JP, / et al.: Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. / Pediatr Infect Dis J 2005, 24 (9) : 807-6. CrossRef
  32. Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, / et al.: Evaluation of RIX4414 a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. / J Infect Dis 2005, 192 Suppl 1: S6-S16. CrossRef
  33. Murray CJL, Lopez AD, eds: The Global Burden of Disease, Vol. 1 of Global Burden of Disease and Injury Series. Cambridge, MA: Harvard University Press 1996.
  34. Gentsch JR, Woods PA, Ramachandran M, / et al.: Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. / J Infect Dis 1996, 174 (Suppl 1) : S30-S36.
  35. Van Man N, Luan le T, Trach DD, Thanh NT, Van Tu P, Long NT, / et al.: Vietnam Rotavirus Surveillance Network. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance, 1998-003. / J Infect Dis 2005, 192 (Suppl 1) : S127-2. CrossRef
  36. Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F, / et al.: Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. / Lancet 2008, 371 (9619) : 1181-. CrossRef
  37. Van Man N, Van Trang N, Lien HP, / et al.: The epidemiology and disease burden of rotavirus in Vietnam: sentinel surveillance at 6 hospitals. / J Infect Dis 2001, 183: 1707-2. CrossRef
  38. WHO: Estimated rotavirus deaths for children under 5 years of age: 2004. [http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html]
  39. WHO: Vaccine Introduction Guidelines: Adding a vaccine to a national immunization programme: decision and implementation. Geneva: WHO 2005.
  40. Parashar UD, Glass RI: Public health. Progress toward rotavirus vaccines. / Science 2006, 312 (5775) : 851-. CrossRef
  41. The Government of the Socialist Republic of Vietnam: Financial Sustainability Plan for Immunization Services 2004.
  42. WHO: WHO/IVB/05.10.Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the costs of rotavirus diarrhea. World Health Organization
  43. WHO: WHO/V&B/02.15. Generic protocols for (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community-based survey on utilization of health care services for gastroenteritis in children. Field test version.
  44. Edejer TT, Aikins M, Black R, / et al.: Cost effectiveness analysis of strategies for child health in developing countries. / BMJ 2005, 331: 1177-2. CrossRef
  45. World Bank: World Development Indicators. [http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20398986~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html]
  46. Doan LT, Okitsu S, Nishio O, Pham DT, Nguyen DH, Ushijima H: Epidemiological features of rotavirus infection among hospitalized children with gastroenteritis in Ho Chi Minh City, Vietnam. / J Med Virol 2003, 69: 588-4. CrossRef
  47. Murray CJL, Lopez AD: The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press 1996.
  48. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/9/29/prepub
  
• 作者单位：Sun-Young Kim (1) (3)
  Sue J Goldie (1) (3)
  Joshua A Salomon (1) (2) (3)
  
  1. Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
  3. Harvard Initiative for Global Health, Cambridge, MA, USA
  2. Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA
  
• ISSN：1471-2458

文摘

Background Rotavirus is the most common cause of severe diarrhea leading to hospitalization or disease-specific death among young children. New rotavirus vaccines have recently been approved. Some previous studies have provided broad qualitative insights into the health and economic consequences of introducing the vaccines into low-income countries, representing several features of rotavirus infection, such as varying degrees of severity and age-dependency of clinical manifestation, in their model-based analyses. We extend this work to reflect additional features of rotavirus (e.g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection), and assess the influence of the features on the cost-effectiveness of rotavirus vaccination. Methods We developed a Markov model that reflects key features of rotavirus infection, using the most recent data available. We applied the model to the 2004 Vietnamese birth cohort and re-evaluated the cost-effectiveness (2004 US dollars per disability-adjusted life year [DALY]) of rotavirus vaccination (Rotarix?) compared to no vaccination, from both societal and health care system perspectives. We conducted univariate sensitivity analyses and also performed a probabilistic sensitivity analysis, based on Monte Carlo simulations drawing parameter values from the distributions assigned to key uncertain parameters. Results Rotavirus vaccination would not completely protect young children against rotavirus infection due to the partial nature of vaccine immunity, but would effectively reduce severe cases of rotavirus gastroenteritis (outpatient visits, hospitalizations, or deaths) by about 67% over the first 5 years of life. Under base-case assumptions (94% coverage and $5 per dose), the incremental cost per DALY averted from vaccination compared to no vaccination would be $540 from the societal perspective and $550 from the health care system perspective. Conclusion Introducing rotavirus vaccines would be a cost-effective public health intervention in Vietnam. However, given the uncertainty about vaccine efficacy and potential changes in rotavirus epidemiology in local settings, further clinical research and re-evaluation of rotavirus vaccination programs may be necessary as new information emerges.